Phase III, Double-blind, Randomized, Multicenter Study of Exogenous Prostaglandin Comparing the Efficacy & Safety of the MVI 200 mcg Versus the Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery in Pregnant Women at Term

Trial Profile

Phase III, Double-blind, Randomized, Multicenter Study of Exogenous Prostaglandin Comparing the Efficacy & Safety of the MVI 200 mcg Versus the Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery in Pregnant Women at Term

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2014

At a glance

  • Drugs Misoprostol (Primary) ; Dinoprostone
  • Indications Labour disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPEDITE
  • Sponsors Cytokine PharmaSciences; Ferring Pharmaceuticals
  • Most Recent Events

    • 13 Oct 2014 According to a company media release, Ferring Pharmaceuticals Ltd, announced today that the Scottish Medicines Consortium (SMC) has accepted its new product MYSODELLE (misoprostol), a retrievable, controlled-release vaginal insert for use in NHS Scotland.
    • 11 Jul 2013 Results published in the Obstetrics and Gynecology.
    • 27 May 2013 Results presented at the First European Congress on Intrapartum Care, according to a Ferring media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top